Promotion of rat hepatocarcinogenesis by praziquantel

Jpn J Cancer Res. 1991 Oct;82(10):1085-8. doi: 10.1111/j.1349-7006.1991.tb01761.x.

Abstract

Praziquantel, the widely used anti-helminthic agent, was investigated for hepatocarcinogenesis-promoting potential using a medium-term liver bioassay system for carcinogens. F344 male rats were given a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg) and then starting 2 weeks later, received praziquantel in the diet at concentrations of 1.5 or 0.5%, or intragastrically at a dose of 1,500 mg/kg once a week for 6 weeks. Control groups received DEN or praziquantel alone. All rats were subjected to two-thirds partial hepatectomy at week 3 and killed at week 8. Development of glutathione S-transferase placental form-positive foci in the liver was significantly increased in terms of both number and area with the 1.5% dose, while only area was affected by the 0.5% dose. The results thus indicate that praziquantel at high dose has promoting potential in rat hepatocytic tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / metabolism
  • Animals
  • Aspartate Aminotransferases / metabolism
  • Body Weight / drug effects
  • Carcinogens
  • Diethylnitrosamine / pharmacology
  • Liver / pathology
  • Liver Neoplasms, Experimental / chemically induced*
  • Organ Size / drug effects
  • Praziquantel / administration & dosage*
  • Rats
  • Rats, Inbred F344
  • gamma-Glutamyltransferase / metabolism

Substances

  • Carcinogens
  • Diethylnitrosamine
  • Praziquantel
  • gamma-Glutamyltransferase
  • Aspartate Aminotransferases
  • Alanine Transaminase